Payment overview · 2025
General Payments
$454.99
7 reported records · 4 companies
Healthcare provider profile · identity verified
Rajiv J Pathak, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · DANA POINT, CA · NPI 1265528111
Verified facts
What the public records show
CMS Open Payments records show Rajiv J Pathak, M.D. received $454.99 in general payments during 2025 across 7 reported records.
AstraZeneca Pharmaceuticals LP accounted for 82.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $376.76 | 82.8% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $33.50 | 7.4% | 2 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28.79 | 6.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.94 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $454.99 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $259.94 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $160.57 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $116.82 | 1 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $28.79 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.31 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.94 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.94 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.19 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 125 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
125 | 44 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
46 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 428 | 178 |
| Levothyroxine Sodium | Levothyroxine Sodium | 417 | 150 |
| Amlodipine Besylate | Amlodipine Besylate | 242 | 107 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 241 | 104 |
| Metformin Hcl | Metformin Hcl | 233 | 91 |
| Metoprolol Succinate | Metoprolol Succinate | 229 | 90 |
| Losartan Potassium | Losartan Potassium | 210 | 90 |
| Lisinopril | Lisinopril | 196 | 86 |
| Omeprazole | Omeprazole | 166 | 75 |
| Tamsulosin Hcl | Tamsulosin Hcl | 166 | 78 |
| Meloxicam | Meloxicam | 163 | 82 |
| Duloxetine Hcl | Duloxetine Hcl | 146 | 57 |
| Januvia | Sitagliptin Phosphate | 126 | 38 |
| Farxiga | Dapagliflozin Propanediol | 125 | 44 |
| Alendronate Sodium | Alendronate Sodium | 124 | 47 |
| Gabapentin | Gabapentin | 113 | 51 |
| Famotidine | Famotidine | 105 | 40 |
| Simvastatin | Simvastatin | 103 | 42 |
| Ozempic | Semaglutide | 98 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 94 | 52 |
| Eliquis | Apixaban | 89 | 23 |
| Donepezil Hcl | Donepezil Hcl | 83 | 30 |
| Olanzapine | Olanzapine | 83 | 24 |
| Methylprednisolone | Methylprednisolone | 80 | 71 |
| Prednisone | Prednisone | 79 | 45 |
| Fluticasone Propionate | Fluticasone Propionate | 77 | 54 |
| Montelukast Sodium | Montelukast Sodium | 74 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 67 | 42 |
| Amoxicillin | Amoxicillin | 67 | 59 |
| Azithromycin | Azithromycin | 65 | 55 |
| Diclofenac Sodium | Diclofenac Sodium | 63 | 36 |
| Trazodone Hcl | Trazodone Hcl | 63 | 32 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 62 | 28 |
| Glimepiride | Glimepiride | 61 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 61 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 58 | 19 |
| Furosemide | Furosemide | 53 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 51 | 14 |
| Finasteride | Finasteride | 49 | 22 |
| Jardiance | Empagliflozin | 46 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 45 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 44 | 40 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 43 | 37 |
| Terazosin Hcl | Terazosin Hcl | 43 | 17 |
| Memantine Hcl | Memantine Hcl | 41 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 41 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 40 | 16 |
| Propranolol Hcl Er | Propranolol Hcl | 40 | 15 |
| Topiramate | Topiramate | 40 | 16 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 39 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 39 | 15 |
| Metformin Hcl Er | Metformin Hcl | 38 | 25 |
| Allopurinol | Allopurinol | 37 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 37 | 17 |
| Amantadine | Amantadine Hcl | 36 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 36 | 13 |
| Ketoconazole | Ketoconazole | 34 | 20 |
| Atenolol | Atenolol | 33 | 15 |
| Carvedilol | Carvedilol | 32 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 31 | 13 |
| Valacyclovir | Valacyclovir Hcl | 31 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 29 | 12 |
| Celecoxib | Celecoxib | 28 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 27 | suppressed |
| Ibuprofen | Ibuprofen | 25 | 12 |
| Sertraline Hcl | Sertraline Hcl | 25 | 14 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 24 | 13 |
| Folic Acid | Folic Acid | 24 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 23 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 22 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Easy Comfort Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Rybelsus | Semaglutide | 21 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 20 | 14 |
| Prolia | Denosumab | 20 | 15 |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 19 | suppressed |
| Metronidazole | Metronidazole | 19 | 15 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | 12 |
| Trulicity | Dulaglutide | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | 11 |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Acetazolamide | Acetazolamide | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 13 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 11 |
| Irbesartan | Irbesartan | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Budesonide Ec | Budesonide | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Kerendia | Finerenone | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Nabumetone | Nabumetone | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $454.99 · 7 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, FARXIGA, MOUNJARO, QULIPTA, UBRELVY, ULTOMIRIS, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error